Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Intravitreal Bevacizumab for Diabetic Macular Edema

Authors not listed

Isfahan Ophthalmology Research Center

Abstract

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-09 MST

Cite this

APA
Anonymous. (n.d.). Intravitreal Bevacizumab for Diabetic Macular Edema. <em>Isfahan Ophthalmology Research Center</em>. https://clinicaltrials.gov/study/NCT00703235
Vancouver
Anonymous. Intravitreal Bevacizumab for Diabetic Macular Edema. Isfahan Ophthalmology Research Center.
BibTeX
@misc{anonndIntrav, title = {Intravitreal Bevacizumab for Diabetic Macular Edema}, author = {Anonymous}, journal = {Isfahan Ophthalmology Research Center}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings